Rethinking bone quality after FDA qualification of total hip BMD as a surrogate endpoint
Related Experiment Video
Updated: Nov 10, 2026
08:04
Proximal Cadaveric Femur Preparation for Fracture Strength Testing and Quantitative CT-based Finite Element Analysis
Published on: March 11, 2017
1Nadogaya Hospital, Shin-kashiwa, Kashiwa, Chiba, 277-0084, Japan.
Bone Reports
|November 9, 2026
Abstract:
•FDA qualified 24-month total hip BMD change as a surrogate endpoint.•What BMD leaves unexplained should not all be labeled bone quality.•Bone quality should denote specified, testable skeletal properties.•Candidate measures require validation matched to their intended use.
